CoChat
Sign Up
Cited by 55Hypothalamic control of reproductive hormonesSexual Differentiation and DisordersGenetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities

Bicalutamide and Third-Generation Aromatase Inhibitors in Testotoxicosis

Open access
Lenz, Anne M., Shulman, Dorothy, Eugster, Erica A., Rahhal, Samar, Fuqua, John S., Pescovitz, Ora H., Lewis, Katherine A.·2010·Pediatrics
DOI 10.1542/peds.2010-0596PMC PMC4096839
Open this paper in CoChat — free account

Abstract

Testotoxicosis, a form of gonadotropin-independent precocious puberty, results from an activating mutation of the luteinizing hormone receptor expressed in testicular Leydig cells. Affected males experience early testosterone secretion, virilization, advancing bone age, and resultant short stature. Recently, the use of combination therapy with a potent antiandrogen agent (bicalutamide) and a third-generation aromatase inhibitor (anastrozole or letrozole) was reported to yield encouraging short-term results. We present here the results of longer-term treatment (4.5 and 5 years) with this combination therapy in 2 boys who demonstrated that it is well tolerated, slows bone-age advancement in the face of continued linear growth, and prevents progression of virilization.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1542/peds.2010-0596

Cites

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Uncontrolled studies using anastrozole, testolactone or letrozole have shown some evidence for a positive effect on sperm concentration and motility.

    “Uncontrolled studies using anastrozole, testolactone or letrozole have shown some evidence for a positive effect on sperm concentration and motility [49-51].”

    From Aromatase inhibitors in men: effects and therapeutic options (2011) · cites this paper as [50]

    The Abstract and Discussion describe anastrozole, testolactone, and letrozole in the treatment of testotoxicosis, with outcomes such as growth and predicted adult height. Searches for sperm concentration, motility, and semen outcomes found no passage reporting that these treatments improved either sperm measure. (LLM, conf=0.74)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

No citation lists for this paper

No citation lists for this paper yet — checked again daily.

References 34 · Cited by 55

Research works printed but not linked: 28

  1. [1]Shenker A Laue L Kosugi S Merendino JJ Jr Minegishi T Cutler GB Jr A constitutively activating mutation of the luteinizing hormone receptor in familial male precocious puberty Nature 1993 365 6447 652 654 7692306
  2. [2]Kawate N Kletter GB Wilson BE Netzloff ML Menon KMJ Identification of constitutively activating mutation of the luteinising hormone receptor in a family with male limited gonadotropin independent precocious puberty (testotoxicosis) J Med Genet 1995 32 7 553 554 7562970 PMC1050550
  3. [3]Schedewie HK Reiter EO Beitins IZ Testicular Leydig cell hyperplasia as a cause of familial sexual precocity J Clin Endocrinol Metab 1981 52 2 271 278 6780588
  4. [4]Rosenthal SM Grumbach MM Kaplan SL Gonadotropin independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases J Clin Endocrinol Metab 1983 57 3 571 579 6223935
  5. [5]Egli CA Rosenthal SM Grumbach MM Montalvo JM Gondos B Pituitary gonadotropin-independent male-limited autosomal dominant sexual precocity in nine generations: familial testotoxicosis J Pediatr 1985 106 1 33 40 3917500
  6. [6]Reiter EO Brown RS Longcope C Beitins IZ Male-limited familial precocious puberty in three generations: apparent Leydig-cell autonomy and elevated glycoprotein hormone alpha subunit N Engl J Med 1984 311 8 515 519 6205273
  7. [7]Reiter EO Narjavaara E Testotoxicosis: current viewpoint Pediatr Endocrinol Rev 2005 3 2 77 86 16361981
  8. [8]Piersma D Verhoef-Post M Berns EM Themmen AP LH receptor gene mutations and polymorphisms: an overview Mol Cell Endocrinol 2007 260–262 282 286 17030087
  9. [9]Latronico AC Segaloff DL Naturally occurring mutations of the luteinizing-hormone receptor: lessons learned about reproductive physiology and G protein-coupled receptors Am J Hum Genet 1999 65 4 949 958 10486313 PMC1288265
  10. [10]Clapham DE Signal transduction: why testes are cool Nature 1994 371 6493 109 110 8072540
  11. [11]Bertelloni S Baroncelli GI Lala R Long-term outcome of male-limited gonadotropin-independent precocious puberty Horm Res 1997 48 5 235 239 9362394
  12. [13]Rajfer J Sikka S Rivera F Handelsman DJ Mechanism of inhibition of human testicular steroidogenesis by oral ketoconazole J Clin Endocrinol Metab 1986 63 5 1193 1198 3760119
  13. [14]Holland FJ Fishman L Bailey JD Fazekas AT Ketoconazole in the management of precocious puberty not responsive to LHR-Hanalogue therapy N Engl J Med 1985 312 16 1023 1028 2984563
  14. [15]Corvol P Michaund A Menard J Freifeld M Mahoudeau J Antiandrogenic effect of spironolactones: mechanism of action Endocrinology 1975 97 1 52 58 166833
  15. [16]Soriano-Guillén L Lahlou N Chauvet G Roger M Chaussain JL Carel JC Adult height after ketoconazole treatment in patients with familial male-limited precocious puberty J Clin Endocrinol Metab 2005 90 1 147 151 15522928
  16. [17]Babovic-Vuksanovic D Donaldson MD Gibson NA Wallace AM Hazards of ketoconazole therapy in testotoxicosis Acta Paediatr 1994 83 9 994 997 7819701
  17. [18]Almeida MQ Brito VN Lins TS Longterm treatment of familial male-limited precocious puberty (testotoxicosis) with cyproterone acetate or ketoconazole Clin Endocrinol (Oxf) 2008 69 1 93 98 18088394
  18. [19]Best TR Jenkins JK Murphy FY Nicks SA Bussell KL Vesely DL Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy Am J Med 1987 82 3 Spec No 676 680 3826130
  19. [20]Laue L Kenigsberg D Pescovitz OH Treatment of familial male precocious puberty with spironolactone and testolactone N Engl J Med 1989 320 8 496 5022492636 2492636
  20. [21]Laue L Jones J Barnes KM Cutler GB Jr Treatment of familial male precocious puberty with spironolactone, testolactone, and deslorelin J Clin Endocrinol Metab 1993 76 1 151 155 8421081
  21. [22]Leschek EW Jones J Barnes KM Hill SC Cutler GB Jr Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset J Clin Endocrinol Metab 1999 84 1 175 178 9920079
  22. [23]Furr BJ The development of Casodex (bicalutamide): preclinical studies Eur Urol 1996 29 suppl 2 83 95 8717469
  23. [24]Morishima A Grumbach M Simpson E Fisher C Qin K Aromatase deficiency in male and female siblings caused by a novel mutation and the physiological role of estrogens J Clin Endocrinol Metab 1995 80 12 3689 3698 8530621
  24. [25]Dunkel L Use of aromatase inhibitors to increase final height Mol Cell Endcrinol 2006 254–255 207 216 16766117
  25. [29]Geisler J Lonning PE Aromatase inhibition: translation into a successful therapeutic approach Clin Cancer Res 2005 11 8 2809 2821 15837728
  26. [30]Eyssette-Guerreau S Pinto G Sultan A Le Merrer M Sultan C Polak M Effectiveness of anastrozole and cyproterone acetate in two brothers with familial male precocious puberty J Pediatr Endocrinol Metab 2008 21 10 995 1002 19209621
  27. [31]Mauras N O’Brien KO Klein KO Hayes V Estrogen suppression in males: metabolic effects J Clin Endocrinol Metab 2000 85 7 2370 2377 10902781
  28. [33]Hayes FJ Seminara SB Decruz S Boepple PA Crowley WF Jr Aromatase inhibition in the human male reveals a hypothalamic site of estrogen feedback J Clin Endocrinol Metab 2000 85 9 3027 3035 10999781

Authors
Lenz, A. M., Shulman, D., Eugster, E. A., Rahhal, S., Fuqua, J. S., Pescovitz, O. H., & Lewis, K. A.
Affiliations
  • University of South Florida (US)
  • Johns Hopkins All Children's Hospital (US)
  • Riley Hospital for Children (US)
  • Ascension (US)
  • University of Michigan (US)
ORCID
Venue
Pediatrics
Publisher
American Academy of Pediatrics (AAP)
Published
2010-09-01
Volume
126
Issue
3
Pages
e728-e733
ISSN
  • 0031-4005 (ISSN-L)
  • 1098-4275
DOI
10.1542/peds.2010-0596
PMC
PMC4096839
OpenAlex
W2020675373
Cited by
55
References
34
Citations by year
2026: 2 · 2025: 3 · 2024: 5 · 2023: 4 · 2022: 4 · 2020: 3 · 2019: 5 · 2018: 5 · 2017: 2 · 2016: 4 · 2015: 4 · 2014: 3 · 2013: 6 · 2012: 1
FWCI
4.19
Type
journal article
Language
en
Open access
Locations
  • PEDIATRICS (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
National Institute of Diabetes and Digestive and Kidney Diseases (T32DK065549)
Topics
  • Health Sciences › Medicine › Reproductive Medicine › Hypothalamic control of reproductive hormones
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sexual Differentiation and Disorders
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Clinical Aspects of Sex Determination and Chromosomal Abnormalities
Keywords
testotoxicosis, bicalutamide, aromatase inhibitors, anastrozole, letrozole, precocious puberty, antiandrogen therapy, bone age, masculinization, short stature, long-term treatment outcomes
MeSH terms
Letrozole, Anastrozole, Androgen Antagonists, Anilides, Child, Preschool, Humans, Male, Nitriles, Puberty, Precocious, Testosterone, Tosyl Compounds, Triazoles, Aromatase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review